Pancreatic Cancer Research

ResearcherUniversity of UtahActive in the last 2 years

Thilo Hackert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7012-1196; OpenAlex author ID A5000483058, A5109974215, A5130007042, A5137748193. Sources: OpenAlex.

Their work

Papers
243 (first author 19, last author 14)
Trials
0
Grants
0
Labs led
3
Collaborators
600
Papers, trials and grants by year

2011: 3 papers · 2012: 6 papers · 2013: 4 papers · 2014: 1 paper · 2015: 6 papers · 2016: 11 papers · 2017: 18 papers · 2018: 17 papers · 2019: 24 papers · 2020: 23 papers · 2021: 38 papers · 2022: 13 papers · 2023: 32 papers · 2024: 13 papers · 2025: 19 papers · 2026: 15 papers

Papers 50 of 243

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. RARRES1 marks an immune-cold, chemoresistance-associated malignant epithelial subpopulation enriched in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-026-04361-8↗
  3. Concordance between GPT-4 and a multidisciplinary tumor board in pancreatic cancer: A prospective pilot study. Co-author DOI 10.1007/s00423-026-04242-9↗
  4. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  5. New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer. First author DOI 10.1038/s41416-025-03295-9↗
  6. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  7. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  8. NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer. Co-author DOI 10.1093/jnci/djaf345↗
  9. Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC. Co-author DOI 10.1097/mpa.0000000000002553↗
  10. Preoperative Surgical or Endoscopic Bile Duct Drainage in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006407↗
  11. Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Resection: A Retrospective Cohort Study. Co-author DOI 10.1245/s10434-025-18698-4↗
  12. ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after Pancreatic Cancer Resection: A Retrospec… Co-author DOI 10.1245/s10434-025-18864-8↗
  13. Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19264-2↗
  14. Blood-based prediction and early detection of pancreatic cancer recurrence after tumor resection Co-author DOI 10.20892/j.issn.2095-3941.2025.0495↗
  15. Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation? Co-author DOI 10.21037/hbsn-2025-587↗
  16. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  17. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  18. Patient-derived tumor organoids highlight the potential of precision medicine in managing pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35443↗
  19. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Co-author DOI 10.1002/ueg2.12676↗
  20. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  21. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  22. Characterization of single neurons reprogrammed by pancreatic cancer. Co-author DOI 10.1038/s41586-025-08735-3↗
  23. Radical antegrade modular pancreatosplenectomy versus conventional left pancreatectomy for pancreatic cancer: study protocol for the multicentre randomized cli… Co-author DOI 10.1093/bjsopen/zraf169↗
  24. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  25. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  26. Early Detection of Sporadic Pancreatic Cancer Co-author DOI 10.1159/000545424↗
  27. Early Detection of Pancreatic Cancer First author DOI 10.1159/000546203↗
  28. Surgery of Early-Stage Pancreatic Cancer. Last author DOI 10.1159/000546416↗
  29. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  30. Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03262-x↗
  31. Retraction Note: Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming. Co-author DOI 10.1186/s13046-025-03339-1↗
  32. Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4. Co-author DOI 10.1200/jco-25-00333↗
  33. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  34. Development of a hypoxia-responsive macrophage prognostic model using single-cell and bulk RNA sequencing in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0322618↗
  35. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  36. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  37. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response. Co-author DOI 10.1016/j.tranon.2024.102109↗
  38. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  39. Performance of different CT enhancement quantification methods as predictors of pancreatic cancer recurrence after upfront surgery. Co-author DOI 10.1038/s41598-024-70441-3↗
  40. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  41. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  42. Correction: Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming. Co-author DOI 10.1186/s13046-024-03216-3↗
  43. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  44. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  45. Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.28527↗
  46. Immunohistochemical FAP Expression Reflects 68Ga-FAPI PET Imaging Properties of Low- and High-Grade Intraductal Papillary Mucinous Neoplasms and Pancreatic Duc… Co-author DOI 10.2967/jnumed.123.266393↗
  47. Intraoperative end-tidal carbon dioxide levels are not associated with recurrence-free survival after elective pancreatic cancer surgery: a retrospective cohor… Co-author DOI 10.3389/fmed.2024.1442283↗
  48. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  49. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Co-author DOI 10.1016/j.annonc.2023.08.009↗
  50. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗

Closest collaborators

The 25 strongest of 600 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Markus Wolfgang Büchler · 83 shared papers, 2011–2026 · strength 9.86
  2. Oliver Strobel · 64 shared papers, 2011–2026 · strength 6.03
  3. John P. Neoptolemos · 35 shared papers, 2016–2026 · strength 4.85
  4. Christoph Springfeld · 28 shared papers, 2013–2026 · strength 4.21
  5. Thomas P. Hank · 24 shared papers, 2015–2026 · strength 3.89
  6. Martin Loos · 16 shared papers, 2021–2026 · strength 3.15
  7. Ulla Klaiber · 21 shared papers, 2018–2023 · strength 2.87
  8. Christoph W. Michalski · 18 shared papers, 2016–2026 · strength 2.84
  9. Nathalia A. Giese · 26 shared papers, 2012–2026 · strength 2.65
  10. Matthias M. Gaida · 22 shared papers, 2011–2025 · strength 2.36
  11. Marc G. Besselink · 16 shared papers, 2018–2026 · strength 1.90
  12. Mohammed Al‐Saeedi · 7 shared papers, 2022–2026 · strength 1.56
  13. Ulrike Heger · 10 shared papers, 2019–2026 · strength 1.56
  14. Rosa Klotz · 9 shared papers, 2020–2026 · strength 1.53
  15. Philipp Mayer · 12 shared papers, 2018–2024 · strength 1.51
  16. André L. Mihaljević · 11 shared papers, 2017–2023 · strength 1.37
  17. Miriam Klauß · 11 shared papers, 2016–2024 · strength 1.36
  18. Markus K. Diener · 10 shared papers, 2019–2025 · strength 1.33
  19. Carl-Stephan Leonhardt · 7 shared papers, 2018–2026 · strength 1.31
  20. Jörg Kaiser · 10 shared papers, 2017–2024 · strength 1.31
  21. Paula Ghaneh · 10 shared papers, 2016–2026 · strength 1.29
  22. Faik Güntac Uzunoglu · 6 shared papers, 2023–2026 · strength 1.27
  23. Susanne Roth · 8 shared papers, 2019–2024 · strength 1.25
  24. Marco Del Chiaro · 9 shared papers, 2019–2026 · strength 1.24
  25. Bas Groot Koerkamp · 9 shared papers, 2019–2026 · strength 1.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.